slotinfini88bonus100| [Research Express] Warner Pharmaceutical Factory received surveys from CITIC Securities Co., Ltd. and other institutions

Warner Pharmaceuticals announced on May 24. From May 14 to May 23, the company received surveys from CITIC Securities Co., Ltd. and other institutions. The receptionists were Dou Lin, Secretary of the Board of Directors and Deputy General Manager, and Qiao, Securities Affairs Representative, conducted through a conference call.

Main content of the survey

1. Introduction to the basic situation of the company 2. Interactive Q & A for investors 1. Please introduce the company's brovudine tablets. Brovudine tablets are suitable for the early treatment of adult patients with acute herpes zoster with normal immune function. Brovudine is a substance closely similar to nucleosides that inhibits the replication of varicella zoster (VZV). In virus-infected cells, brovudine undergoes a series of phosphorylation, and the intracellular phosphate conversion process is caused by the viral thymidine kinase...

List of recipients

Institutional research and backtesting

In addition to the same day, Warner Pharmaceutical Co., Ltd. has received a total of 310 surveys from 186 institutions in the past year. The survey and back-testing results in the past ten announcement days are shown in the following table:

Institutional research and backtesting in the past year

Note: 1slotinfini88bonus100. In this paper, the calculation of excess return adopts a market-adjusted model, using the Shanghai and Shenzhen 300 Index as the benchmark index, and excess return = actual rate of return-benchmark rate of returnslotinfini88bonus100;2. "Recent year" refers to the recent year as of the latest announcement date.

Market institution research

On May 24, Shengyi Technology, Huatie Emergency, Canxin, Bull Group, SaiMicroelectronics, Ankerui and other companies successively issued institutional research announcements. The details are as follows:

Survey of Shanghai and Shenzhen institutions

Disclaimer: This article is based on big data production and is for reference only. It does not constitute any investment advice. Therefore, the operation risks are at your own risk.